Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2014-03-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/1389557514666140428105753PMID 24766386
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.

  2013cited by this paper
• The endocannabinoid signaling system in cancer.

  2013cited by this paper
• Design, synthesis, and pharmacological properties of new heteroarylpyridine/heteroarylpyrimidine derivatives as CB(2) cannabinoid receptor partial agonists.

  2013cited by this paper
• Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists.

  2013cited by this paper
• Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

  2013cited by this paper
• Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening.

  2013cited by this paper
• Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.

  2013cited by this paper
• Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.

  2013cited by this paper
• Endocannabinoids in nervous system health and disease: the big picture in a nutshell

  2012cited by this paper
• Towards the use of cannabinoids as antitumour agents

  2012cited by this paper
• CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.

  2012cited by this paper
• Structure-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic action.

  2012cited by this paper
• Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.

  2012cited by this paper
• Discovery and optimization of novel purines as potent and selective CB2 agonists.

  2012cited by this paper
• Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.

  2012cited by this paper
• 7-Oxo-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamides as selective CB(2) cannabinoid receptor ligands: structural investigations around a novel class of full agonists.

  2012cited by this paper
• Synthesis and evaluation of 2-amido-3-carboxamide thiophene CB₂ receptor agonists for pain management.

  2012cited by this paper
• Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.

  2012cited by this paper
• Investigations on the 4‐Quinolone‐3‐Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid‐2 Receptor Ligands through a Bioisosteric Approach

  2012cited by this paper
• 4-Oxo-1,4-dihydropyridines as selective CB₂ cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis.

  2012cited by this paper
• Selective cannabinoid receptor 2 modulators: a patent review 2009 – present

  2012cited by this paper
• Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.

  2011cited by this paper
• Endocannabinoids in liver disease

  2011cited by this paper
• Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain.

  2011cited by this paper
• 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.

  2011cited by this paper
• Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.

  2011cited by this paper
• Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.

  2011cited by this paper
• Cannabinoids: occurrence and medicinal chemistry.

  2011cited by this paper
• Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.

  2011cited by this paper
• Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

  2011cited by this paper
• The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning?

  2010cited by this paper
• Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB(2) agonists for the treatment of inflammatory pain.

  2010cited by this paper
• Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.

  2010cited by this paper
• Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies

  2010cited by this paper
• Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.

  2010cited by this paper
• Cannabinoids and the immune system: an overview.

  2010cited by this paper
• Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.

  2010cited by this paper
• Cannabinoids and experimental models of multiple sclerosis.

  2010cited by this paper
• 4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.

  2010cited by this paper
• Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?

  2009cited by this paper
• CB2 selective sulfamoyl benzamides: optimization of the amide functionality.

  2009cited by this paper
• Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation

  2009cited by this paper
• Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.

  2009cited by this paper
• 2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.

  2009cited by this paper
• Latest advances in cannabinoid receptor agonists

  2009cited by this paper
• Cannabinoids and Parkinson's disease.

  2009cited by this paper
• Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.

  2008cited by this paper
• Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.

  2008cited by this paper
• Cannabinoid receptors and the regulation of bone mass

  2008cited by this paper
• End of the line for cannabinoid receptor 1 as an anti-obesity target?

  2008cited by this paper
• Targeting the endocannabinoid system: to enhance or reduce?

  2008cited by this paper
• New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.

  2007cited by this paper
• Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant?

  2007cited by this paper
• Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.

  2007cited by this paper
• Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.

  2007cited by this paper
• The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis.

  2006cited by this paper
• Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

  2006cited by this paper
• Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.

  2006cited by this paper
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy

  2006cited by this paper
• Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain

  2006cited by this paper
• Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.

  2006cited by this paper
• Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

  2004cited by this paper
• Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors.

  2004cited by this paper
• The therapeutic potential of cannabis.

  2003cited by this paper
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cited by this paper
• SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

  1998cited by this paper
• Pharmacology of cannabinoid CB1 and CB2 receptors.

  1997cited by this paper
• Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.

  1996cited by this paper
• Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

  1995cited by this paper
• 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.

  1995cited by this paper
• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

  1994cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

  1992cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper

• Unraveling Endocannabinoid Signaling Pathways in Cisplatin‐Induced Ototoxicity

  2026cites this paper
• Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).

  2024cites this paper
• Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present)

  2024cites this paper
• Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

  2023cites this paper
• Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits

  2022cites this paper
• Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential.

  2022cites this paper
• Modern Approaches to the Development of Synthetic Cannabinoid Receptor Probes.

  2021cites this paper
• Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.

  2021cites this paper
• The Acute Activation of the CB1 Receptor in the Hippocampus Decreases Neurotoxicity and Prevents Spatial Memory Impairment in Rats Lesioned with β-Amyloid 25-35.

  2019cites this paper
• Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB2R Ligands

  2018cites this paper
• Chapter 10 Cannabinoids : Drug or Medication ?

  2018cites this paper
• Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.

  2017cites this paper
• Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients.

  2017cites this paper
• Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.

  2017cites this paper
• Cannabinoids: Drug or Medication?

  2016cites this paper
• Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer's disease.

  2016cites this paper
• Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

  2016cites this paper
• Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

  2016cites this paper
• Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update

  2016cites this paper
• Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.

  2015cites this paper
• MINIREVIEW CB 2 Cannabinoid Receptors as a Therapeutic Target — What Does the Future Hold ?

  2014cites this paper
• CB 2 Cannabinoid Receptors as a Therapeutic Target — What Does the Future Hold ?

  2014cites this paper
• CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?

  2014cites this paper